Article

Evidence Backs Acetaminophen as "Mainstay" for OA Pain in Elderly

A literature review suggests that in older patients with osteoporosis, the risks of NSAIDs may outweigh their benefits.

For non-frail elderly patients with osteoarthritis (OA), there are good reasons to prefer acetaminophen or even opioids over NSAIDs. This is the outcome of an extensive literature review by authors from Duquesne University, the University of Pittsburgh, and the Pittsburgh VA system.

Looking specifically for studies that examined the use of analgesics for osteoarthritis among patients over the age of 65,the authors went beyond searching in databases of medical literature to scrutinize the citations for further studies.

It is now "well-established," they say, that the risks for gastrointestinal toxicity and kidney damage as a result of NSAID use are increased among elderly individuals, while the evidence of increased risk for liver damage from acetaminophen in older patients is "limited." For treatment of severe osteoarthritis pain, they add, except for elderly patients with a history of opioid misuse the advantages of pain control may outweigh the risks.

Acetaminophen should be the "mainstay" of OA treatment in this age group, they conclude, while NSAIDs are best considered for short-term use only.

The article "Adverse Effects of Analgesics Commonly Used by Older Adults With Osteoarthritis: Focus on Non-Opioid and Opioid Analgesics" appears in the American Journal of Geriatric Pharmacotherapy.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.